Clinical Trial

Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy

Study acronym: EMERGE
Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
The sponsor determined that enrollment would not meet their expectations and decided to withdraw the study.
Summary
The goal of this research study is to better understand if there is an association between non-alcoholic fatty liver disease (NAFLD) and active psoriatic disease (PD), and to assess the effect of Guselkumab (a medication approved by the FDA instead of the standard of care to treat PD), for NAFLD patients who receive Guselkumab for their PD.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-20.
Status change: Not Yet Recruiting → Withdrawn 2026-02-19
Trial Details
NCT Number NCT07255781
Lead Sponsor University of California, San Diego
Collaborators: Janssen Scientific Affairs, LLC
Conditions Psoriasis (PsO), PsA (Psoriatic Arthritis), NAFLD (Nonalcoholic Fatty Liver Disease)
Start Date 2025-11-30
Primary Completion 2025-11-30 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-23